drugset / Trial / NCT02703051
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
RandomizedSingle-groupSingle-blindOther
Summary
Phase 1, open-label, parallel, active-controlled, multiple IV dose, proof of concept study conducted at one study center in the United States (US).
Timeline
- Start
- 2015-11
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Uproleselan | Small molecule | — | — |
| Subject | filgrastim | Protein / enzyme biologic | — | — |
Indications
No indication recorded.